



# Transplant Complication Working party

Chair : Grzegorz basak

Secretary : Zina Peric

GvHD subcom : Olaf Penac

Survivorship subcom : Helene Schoemans

Regimen-related Tox subcom: Christian Koenecke

## PUBLICATIONS 2020

Nutritional support in stem cell transplantation programs: Results from a multicenter survey of nurses on behalf of the Nurses Group and Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation and the Gruppo Italiano Trapianto di Midollo Osseo;

**Stefano Botti**

Reduced Calcium Signaling Is Associated With Severe Graft-Versus-Host Disease: Results From Preclinical Models and From a Prospective EBMT Study; **Katarina Riesner**

Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMT; **Andrzej Frankiewicz**

Investigation and Management of Bone Mineral Density Following HCT: A Survey of Current Practice by the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation; **Nina Salooja**

Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT - A Prospective, Non-interventional Study of the EBMT Transplant Complications Working Party; **Olaf Penack**

Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP); **Robert David Sandler**

Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.; **Olaf Penack**

Frequency of lethal central nervous system neurotoxicity in patients undergoing allogeneic stem cell transplantation: a retrospective registry analysis; . **Schultze-Florey CR**,

How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT.; **Olaf Penack**

Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation - a prospective, non-interventional study of the EBMT Transplant Complication Working Party.; **Penack O**,

## SUBMITTED PAPER

- **Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT. (Olaf Penack)**

## OTHER

- **Joint study with IDWP on Risk Factors and Frequency of Lethal Central Nervous System Toxicity in Allogeneic Stem Cell Transplantation (C. Schultze-Florey & M. Schmidt)**

## COMING SOON CALL FOR PARTICIPATION & DATA COLLECTION

- **Autoimmune and Inflammatory Diseases (AIID) post Allogeneic Haematopoietic Cell Transplantation (HCT): a joint retrospective study of the TCWP and ADWP (A Mekinian)**

Based on a large European registry, this study aims to evaluate the incidence of AIIDs after allogeneic transplantation, factors associated with these disorders, including graft-versus-host disease, the onset and the impact of the presence of AIIDs on survival.

### Primary end point:

Incidence of inflammatory and autoimmune diseases after allogeneic HSCT in adult patients

### Secondary end points:

1. Correlate AIIDs occurrence to GVH types and outcome, and identify factors associated with AIIDs occurrence
2. Survival outcomes (OS, NRM and event free survival)

- **Outcomes of ECP in combination with new treatment protocols in Acute and Chronic GvHD (O. Penack)**

**Objectives:** The main objective is compare and to evaluate the safety and efficacy of patients receiving ECP and/or new treatments in acute and chronic GvHD. The secondary objectives are to evaluate the steroid tapering and sparing effects of patients treated with ECP and/or new treatments, to describe the patient characteristics of patients receiving ECP and/or new treatments, and to describe the usage, sequencing and dosage of ECP with new treatment combinations in acute and chronic GvHD

### Study population:

Acute GvHD patients with HSCT who have failed steroids and developed Steroid Refractory-GvHD and are treated with either ECP or/and Ruxolitinib.

Patients with HSCT who have developed chronic GvHD and failed to respond to steroids (Steroid Refractory-cGvHD) and are treated with either ECP or/and Ruxolitinib or/and Ibrutinib.

Recruiting period 2017-2019

**Type of study:** Multi-centre retrospective study

**Status of the study:** Currently recruiting

**Study Coordinator:** Jessica Lemaitre ([jessica.lemaitre@ebmt.org](mailto:jessica.lemaitre@ebmt.org))

- **Survey on the Management of Steroid Refractory GvHD (Z. Peric)**

**Objectives:** To evaluate the current „real life” clinical practice in EBMT centres concerning the management of steroid-refractory acute GVHD after allo-HSCT due to hematological malignancies.

**Study Coordinator:** Pascale Ambron ([pascale.ambron@ebmt.org](mailto:pascale.ambron@ebmt.org))

- **Graft rejection in haploidentical HSCT: survey of subsequent therapeutic options (N. Durakovitich)**

**Objectives:** To evaluate the current „real life” clinical practice in EBMT centres concerning the management of graft failure after Haploidentical transplantation.

**Study Coordinator:** Pascale Ambron ([Pascale.Ambron@ebmt.org](mailto:Pascale.Ambron@ebmt.org))

ABSTRACT EBMT 2021	ONGOING & PLANNED ANALYSES	CLOSING DATA COLLECTION
Association of pre-existing co-morbidities with alloSCT outcome - a retrospective analysis (O. Penack)	Survey of clinical practices with the use of anti-thymocyte globulin (ATG) as graft-versus-host disease (GVHD) prevention(A. Piekarska)	EASIX to predict alloSCT outcome (O. Penack) <i>Inclusion closed, ongoing collection of the follow-up</i>
One thousand voices raised for patient engagement in hematopoietic stem cell transplantation and cell therapy: a context analysis from the EBMT (H. Schoemans)	Retrospective study on the incidence, severity, management and outcome of sinusoidal obstruction syndrome/ veno-occlusive disease of the liver (SOS/VOD) in allo HSCT in adult patients (T. Ruutu)	Complications of haploidentical HCT with post-transplant cyclophosphamide - a non-interventional prospective study (G. Basak) <i>Inclusion closed, ongoing collection of the follow-up</i>
		A cross-sectional study on the Sexual Function of Adult Survivors and their partners 3 and 15 years Post allogeneic Stem Cell Transplantation. (C. Eeltink & J.Stringer)
		Fecal microbiota transplantation in the treatment of patients after allogeneic hematopoietic stem cell transplantation (J. Bilinski)